Navigation Links
deCODE Announces Positive Topline Results for Phase I Study of,DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi- dose, ascending dose, placebo-controlled clinical trial, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. Building upon the positive results seen in the Phase I single dose study completed at the end of last year, key results were:

Safety and tolerability: DG051 was well tolerated at all dose levels tested, with no serious adverse events reported.

Dose-dependent reduction of leukotriene B4 (LTB4): DG051 was shown to reduce LTB4 production in a dose-dependent manner, with a peak reduction of more than 70% versus baseline after 7 days of treatment.

Pharmacokinetic profile: DG051 was found to have good bioavailability, with low variability between subjects. With a terminal half-life of approximately 9 hours and measurable concentrations at 24 hours after dosing, DG051 has a pharmacokinetic profile suitable for once-a-day dosing.

"The results of our Phase I trials show DG051 to be well tolerated and to provide a potent means of reining in the activity of the pathway our research has shown to modulate risk of heart attack. This latest study also provides us with pharmacodynamic data suggesting that we may be able to achieve a high steady-state reduction in LTB4 production with a dose in the middle of the range we have tested, and we look forward to entering DG051 into Phase II trials later this year," said Kari Stefansson, CEO of deCODE.

About DG051

DG051 is a first-in-class, small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H) discovered by deCODE's chemistry unit and being developed for the prevention of heart attack. LTA4H is encod
'"/>




Page: 1 2 3

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/6/2009)... -- Philips Respironics applauds the efforts of th... to raise awareness about an important public heal... release of the first-ever government study to mon...s a milestone in quantifying the size and scope of...stry leader and sleep therapy manufacturer, Philip...
(Date:11/6/2009).../ -- Cyberonics, Inc. (Nasdaq: CYBX ) today annou...s for the second quarter ended October 23, 2009 of...y, November 18, 2009 at 5:00 PM EST. The company ...sults on Thursday, November 19, 2009 at 9:00 AM ES... Conference Call Instructions ,, To listen to...
(Date:11/6/2009)... , - Trial Will Compare NXL103 With Leadi...-Resistant Staphylococcus Aureus (MRSA) Infections...ompany focused on the discovery and,development of...icant global,problem of microbial resistance, anno...ial NXL103 (flopristin/linopristin), has started a...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 1Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 2Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 3Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 5Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 6Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 7Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 1DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 2DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 3DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 5DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 6DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 7DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 9DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 10DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 11DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 12DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 13Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 1Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 2
...e many, clinical studies are few, NEW YORK, Aug. ...that a limited amount of clinical research exists,...r (OTC) anti-aging,products. The study is publishe...urgery Journal, the official peer-reviewed journal...gery (ASAPS). OTC anti-aging products represent a...
...tional Stem,Cell Holding, Inc. (OTC: NHGI.PK), tod...y, and Jacob Cohen, have discovered biomaterial de...s to promote tissue repair in,various wound care a...ced that while using its,proprietary embryonic ste...,group of biomaterials that in preclinical studies...
Other Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 3
(Date:11/8/2009)...people in the Western District of Pennsylvania awa...uffering for a medical malpractice case. Attorney...of Thomas E. Crenney and Associates, LLC handled t...ky and against the Uniontown Hospital. The woman ...omy at age 18. , Pittsbur...
(Date:11/8/2009)...battle is won," said Dr. Charmaine Yoest. ,, W...vote of 240-194, the Stupak-Ellsworth-Pitts-Kaptur...bortion mandates and funding in HR 3962 passed on ...ction President and CEO Dr. Charmaine Yoest said, ...e pro-life Americans across this country who have ...
(Date:11/8/2009)...SNewswire/ -- USAction this evening hailed passage...ich will make health care more affordable for cons...crease access to health care for millions of Ameri...lt, FDR and Harry Truman would be proud," said USA... ranks among our country,s proudest achievements. ...
(Date:11/8/2009)... 3961 to Secure the Stability of Medicare ,, H...t Attributable to: J. James Rohack, M.D., Presiden...tp://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO... health reform bill, which will help improve the h... for swift passage of H.R. 3961 to secure the stab...
(Date:11/8/2009)...ealth Care Reform Bill ,, Critical legislatio...all Americans ,, CHICAGO, Nov. 7 /PRNewswire-U...presentatives passed by a vote of 220-215, critica...then Medicare for seniors and end discrimination b...icans out of affordable health coverage. ,, T...
Breaking Medicine News(10 mins):Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3
... for the festive season comprise most of the dengu...ted with the mosquito-borne virus so far.// ... threat of dengue in the state. Most of the ...pcoming Diwali and Chath festivals. In some ...
... to controlling diabetes, says former Pakistan cri...Diabetes can be managed by maintaining a healthy l...r medication and regular monitoring of blood sugar...icketer was speaking at the Accu-Chek Inspiration ...
...y Prize 2007 was awarded to a UK researcher who ha...n that could help to single out somebody's voice i...her and also responsible for training the brain to...most frequently encountered difficulty by over 9 m...
...out huge backlogs of patients for important surger..., who have begun investigating the issue. Accordi...mies, colonoscopies and gallbladder surgeries have...n Medical Association to investigate thoroughly du...
...health revolution that offers cures for cancer, re...alk again.// This is the opinion of Australia’... advances which they consider will transform lives...bined their expertise to look into the future for ...
...in a particular brain area of patients afflicted w...ed// at the Laboratory for Cognitive Neuroscience ...Williams syndrome is a rare genetic disorder where...e, said: "Understanding the connections between mi...
Other Medicine News:Health News:Migrant Bihar Labourers Bring Dengue Home 2Health News:Healthy Lifestyle can Control Diabetes: Wasim Akram 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 3Health News:Tune Your Brain to Hear Another in a Noisy Ambience 4Health News:Age of Medical Miracles has come upon us 2
Arrow QuadPolar EP Catheter
Mayfield Triad Skull Clamp
...umin Strips provide albumin, creatinine and albumi...linitek Microalbumin product is useful to test for...ertension in order to detect early kidney disease....f the urinary albumin excretion rate, is an indica...
Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
Medicine Products: